News from Camurus AB A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 29, 2017, 04:27 ET Camurus Announces European Medicines Agency Validation of CAM2038 Marketing Authorization Application for Treatment of Opioid Dependence

Camurus (NASDAQ STO: CAMX) today announced the company's Marketing Authorization Application (MAA) for the investigational, weekly and monthly...


Sep 18, 2017, 23:20 ET Camurus annonce que la FDA a accordé l'examen prioritaire de la demande d'autorisation du traitement CAM2038

La FDA a fixé une date butoir en vertu de la PDUFA au 19 janvier 2018 pour la demande d'autorisation de l'injection de dépôts hebdomadaires et...


Sep 18, 2017, 09:52 ET Camurus: FDA stimmt für vorrangige Prüfung des NDA-Antrags für wöchentliche und monatliche CAM2038 Buprenorphin-Depots zur Behandlung von Opioidkonsumstörung

FDA legt PDUFA-Entscheidungstermin auf den 19. Januar 2018 Camurus (NASDAQ STO: CAMX) hat bekanntgegeben, dass die US-amerikanische Food and...


Sep 18, 2017, 08:02 ET Camurus anuncia que la FDA concede una revisión prioritaria de NDA para los depósitos de buprenorfina CAM2038 semanales y mensuales para el tratamiento de la enfermedad de uso opioide

La FDA ha asignado una fecha de objetivo PDUFA para el 19 de enero de 2018 Camurus (NASDAQ STO: CAMX) anuncia que la Administración de...


Sep 18, 2017, 04:17 ET Camurus Announces That FDA Grants Priority Review of NDA for Weekly and Monthly CAM2038 Buprenorphine Depots for Treatment of Opioid Use Disorder

The FDA has assigned a PDUFA target date of January 19, 2018 Camurus (NASDAQ STO: CAMX) announces that the U.S. Food and Drug Administration...


Nov 14, 2016, 02:00 ET Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine (CAM2038) for Treatment of Opioid Addiction

- Head-to-head Study of CAM2038 Versus Daily Sublingual Buprenorphine - CAM2038 met Both FDA and EMA Primary Endpoints of...


Nov 20, 2014, 01:00 ET Camurus och Braeburn Pharmaceuticals ingår ett exklusivt licensavtal för långtidsverkande subkutant buprenorfin för behandling av opiatberoende och smärta

Camurus och Braeburn Pharmaceuticals meddelar idag att de ingått ett exklusivt licensavtal för Camurus långtidsverkande...